Stocktoria
MBX Biosciences, Inc. MBX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-09-13
MBX Biosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D expense | $79.2M | $57.4M | $28.5M |
| Operating income | -$98.1M | -$68.2M | -$35.3M |
| Income tax | $0 | $0 | $0 |
| Net income | -$87.0M | -$61.9M | -$32.6M |
| EPS (diluted) | $-2.38 | $-5.82 | $-31.96 |
| Operating cash flow | -$79.9M | -$54.7M | -$32.0M |
| Free cash flow | -$81.9M | -$55.6M | -$32.1M |
| Cash & equivalents | $75.3M | $49.4M | $30.5M |
| Total assets | $385.1M | $268.5M | $84.2M |
| Total liabilities | $15.9M | $11.1M | $4.3M |
| Shareholders' equity | $369.2M | $257.4M | -$72.5M |
Source: SEC EDGAR filings · CIK 0001776111 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.